FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, **SECTION 4(6), AND/OR** IFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL							
OMB Number:	3235-0076						
Expires:	May 31,2005						
Estimated averag	e burden						
hours per respons	se 16.00						

SEC USE ONLY							
Prefix	Serial						
			_				
DATE RECEIVED							
]				

Name of Offering (check if this is an amendment and name has changed, and indicate change.)	71
Series C Preferred Stock Financing 1 (1) 8 ll	10
Filing Under (Check box(es) that apply): ☐ Rule 504 ☐ Rule 505 ☒ Rule 506 ☐ Section 4(6) ☐	ULOE
Type of Filing: New Filing	
A. BASIC IDENTIFICATION DATA	
1. Enter the information requested about the issuer	
Name of Issuer (check if this is an amendment and name has changed, and indicate change.)	
Raven biotechnologies, inc. 02067175	
Address of Executive Offices (Number and Street, City State, Zip Code) Telepho	Je)
270 East Grand Avenue, South San Francisco, CA 94080 (650) 624-2600	
Address of Principal Business Operations (Number and Street, City State, Zip Code) Telephone Number (Including	Area Code)
(if different from Executive Offices)	
Brief Description of Business	CESSED
PRO	CLOOSE
Type of Business Organization	C 5 0 5005
□ business trust □ limited partnership, to be formed □	HONISON "
Month Year	NANCIAL
Actual or Estimated Date of Incorporation or Organization: 0 1 9 9 Actual Estimated	
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: CN for Canada; FN for other foreign jurisdiction)	Е

GENERAL INSTRUCTIONS

Federal: Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This Notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. 10663823v1

SEC 1972 (6-02)

	:	A. BASIC IDENTIF	ICATION DATA						
	 Enter the information requested of the following: Each promoter of the issuer, if the issuer has been organized within the past five years; 								
	• Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% more of a class of equity securities of the issuer;								
	• Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and								
Each general and managing partner of partnership issuers.									
Check Box(es) that Appl	y: Promoter	☑ Beneficial Owner	☑ Executive Officer	☑ Director		General and/or Managing Partner			
Full Name (Last name fir	st, if individual)								
Mather, Jennie P.									
Business or Residence A		•							
			th San Francisco, CA,	· · · · · · · · · · · · · · · · · · ·					
Check Box(es) that Apply	· .	☑ Beneficial Owner	☐ Executive Officer	☑ Director		General and/or Managing Partner			
Full Name (Last name fir	st, if individual)								
Baruch, Thomas		1.6	C 1)						
Business or Residence A		•		0.4000					
*****		Beneficial Owner	th San Francisco, CA, 9 ☐ Executive Officer	94080 ☑ Director		General and/or			
Check Box(es) that Apply	·	Beneficial Owner				Managing Partner			
Full Name (Last name fir	st, if individual)								
Cordaro, Christine Business or Residence Ac	Idraes (Number on	d Street City State 7in	Codo						
		•		0.4000					
Check Box(es) that Apply		■ Beneficial Owner	th San Francisco, CA, S ☐ Executive Officer	☑ Director		General and/or Managing Partner			
Full Name (Last name fir	st, if individual)								
Root, Jonathan D.			•						
Business or Residence A	ddress (Number an	d Street, City, State, Zip	Code)						
c/o Raven biotechne	ologies, inc., 270 F	East Grand Avenue, Sou	ith San Francisco, CA,	94080					
Check Box(es) that Appl	y: Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director		General and/or Managing Partner			
Full Name (Last name fir	st, if individual)								
Lippman, Marc			····						
Business or Residence A	idress (Number an	d Street, City, State, Zip	Code)						
			th San Francisco, CA,	94080					
Check Box(es) that Appl	y: Promoter	☐ Beneficial Owner	☐ Executive Officer	⊠ Director		General and/or Managing Partner			
Full Name (Last name fir Young, Ph.D., Willi									
Business or Residence A		d Street, City, State, Zip	Code)	······································					
c/o Raven biotechne	ologies, inc., 270 H	East Grand Avenue, Soi	ith San Francisco, CA,	94080					
Check Box(es) that Appl		☑ Beneficial Owner	☐ Executive Officer	☐ Director		General and/or Managing Partner			
Full Name (Last name fir	st, if individual)								
U.S. Venture Partn	ers								
Business or Residence A	ddress (Number an	d Street, City, State, Zip	Code)						
c/o Presidio Manag	ement Group VII	, L.L.C., 2735 Sand Hil	l Road, Menlo Park, CA	A 94025 Attn: N	Aicha	iel Maher			

......

Check Box(es) that Apply:	☐ Promoter	☑ Beneficial Owner	☐ Executive Officer	☐ Director		General and/or Managing Partner
Full Name (Last name first, i	f individual)					
CMEA Ventures						
Business or Residence Addre	ess (Number and	d Street, City, State, Zip	Code)			
One Embarcadero Cen	ter, Suite 3250	, San Francisco, CA 94	1111			
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☑ Executive Officer	☐ Director		General and/or Managing Partner
Full Name (Last name first, i	f individual)					
Whelan, John B.						
Business or Residence Addre	ess (Number and	d Street, City, State, Zip	Code)			
c/o Raven biotechnolog	gies, inc., 270 E	ast Grand Avenue, Sou	ıth San Francisco, CA,	94080		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☑ Executive Officer	☐ Director		General and/or Managing Partner
Full Name (Last name first, i	f individual)					
Vehar, Gordon A.						
Business or Residence Addre	ess (Number and	d Street, City, State, Zip	Code)			
c/o Raven biotechnolog	gies, inc., 270 E	ast Grand Avenue, Sou	ıth San Francisco, CA,	94080		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director		General and/or Managing Partner
Full Name (Last name first, i	f individual)					
Business or Residence Address (Number and Street, City, State, Zip Code)						
	(Use bla	nk sheet, or copy and use addi	tional copies of this sheet, as n	ecessary)		

					В. І	NFORM	ATION AF	BOUT OF	FERING				
1.	Has th	ne issuer s	old, or doe	s the issuer	intend to	sell, to no	on-accredite	d investors	in this off	fering?	Yes	1 🗆	Vo ⊠
				A	inswer also	in Append	lix, Column 2	2, if filing u	nder ULOE				
2.	What	is the min	imum inve	stment tha	t will be ac	ccepted fi	om any ind	ividual?		•••••	\$	n/a	
3.	Does	the offerin	ig permit jo	oint owners	ship of a si	ngle unit	?			•••••	Yes	□ 1	√0 ×
	4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.												
Full	Name	(Last nam	ne first, if i	ndividual)									
Rus	iness c	r Residen	ce Address	(Number	and Street	City Sta	ite, Zip Cod	e)					
240.			20 1 1001000	(11011001	51.000,	011), 010	, <u></u>	-,					
Nan	ne of A	ssociated	Broker or	Dealer									
					-		icit Purchas						
	•				•							_	ll States
	. 🗆	AK 🗆	AZ 🗆	AR □	CA 🗆	co 🗆	ст □	DE 🗆	DC 🗆	FL 🗆	GA □	HI 🗆	ID 🗀
	. 🗆	IN 🗆	IA 🗀	ks □ —	KY 🗆	LA 🗆	ME 🗆	MD 🗖	MA 🗆	MI 🗆	MN 🗆	MS □ _	мо 🗆
MT		NE 🗆	NV 🗆	ин 🗆	NJ 🔲	NM 🗆	NY 🗖	NC 🗆	ND 🗆	он 🗆	ок 🗖	OR 🗆	PA 🗆
		sc 🗆	SD 🗆	TN 🗆	TX 🗆	UT 🗆	VT 🗆	VA 🗆	WA 🗆	wv 🗆	WI 🗆	WY 🗆	PR 🗆
Full	Name	(Last nan	ne first, if i	ndividual)									
Bus	iness c	r Residen	ce Address	(Number	and Street,	City, Sta	te, Zip Cod	e)	<u> </u>				
Nan	ne of A	ssociated	Broker or	Dealer									
<u> </u>				TT 0 11 14		1 . 0 1	· : D 1						
							icit Purchas					ПΔ	ll States
	. 🗆	AK 🗆	AZ 🗆	AR 🗆	CA 🗆	со 🗖	ст 🗆	DE 🗆	DC 🗆	FL 🗆	GA □	— 77	ID 🗆
		IN 🗆	IA 🗆	ks □	KY □	LA 🗆	ME 🗆	MD 🗆	ма 🗆	мі 🗆	MN 🗆	MS 🗆	мо 🗆
		NE 🗆	NV 🗆	NH 🗆	NJ 🗆	NM 🗆	NY 🗆	NC 🗆	ND 🗆	он □	ok 🗆	OR 🗆	PA 🗖
		sc 🗆	SD □	TN 🗆	TX 🗆	UT 🗆	VT 🗆	VA 🗆	WA 🗆	wv 🗆	wi 🗆	WY 🗆	PR 🗆
			ne first, if i			<u> </u>					 _		
Bus	iness o	or Residen	ce Address	(Number	and Street,	City, Sta	ite, Zip Cod	e)					
Nan	ne of A	Associated	Broker or	Dealer	, , , , , , , , , , , , , , , , , , ,					= 173.13.		n:n:	
Stat	es in V	Vhich Pers	on Listed	Has Solicit	ed or Inter	ids to Sol	licit Purchas	ers		 -			
												🗆 А	ll States
	. 🗆	AK 🗆	AZ 🗖	AR □	CA 🗆	со 🗆	ст □	DE 🗆	DC 🗆	FL 🗆	GA □	ні 🗆	ID 🗖
IL	. 🗆	IN 🗆	IA 🗖	ks □	KY □	LA 🗖	ме 🗆	MD □	ма 🗆	мі 🗆	MN 🗆	MS □	мо 🗆
MT		NE 🗆	NV 🗆	ин 🗆	NJ 🗖	NM 🗆	NY 🗆	NC 🗆	ND 🗆	он 🗆	ок 🗆	OR 🗆	PA 🗆
R		sc 🗆	sp □	TN 🗆	тх 🗆	UT 🗆		VA 🗆	WA 🗆	wv 🗆	wı 🗆	wy 🗆	PR □

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AN	D USE OF P	ROC	EED	S
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \square and indicate in the columns below the amounts of the securities for exchange and already exchanged.	A		A -	
	Type of Security	Aggregate Offering Pr		At	nount Already Sold
	Debt	\$		\$	
	Equity Deferred	\$ 40,000,00	0.00	\$	35,000,000.63
		Φ.		\$	
		\$			
		\$		\$	
	Other (Specify)			\$	
		\$ 40,000,00	0.00	\$	35,000,000.63
	Answer also in Appendix, Column 3, if filing under ULOE.				
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if the answer is "none" or "zero."	Number		D	Aggregate ollar Amount
		Investors			of Purchases
	Accredited Investors	17		\$	35,000,000.63
	Non-accredited Investors	0		\$	0
	Total (for filings under Rule 504 only)			\$	
	Answer also in Appendix, Column 4, if filing under ULOE.				
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1.	T		.	,
	Type of Offering	Type of Security		D	ollar Amount Sold
	Rule 505			\$	
	Regulation A			\$	
	Rule 504			\$	
	Total			\$	
4.	· · · · · · · · · · · · · · · · · · ·			•	
	Transfer Agent's Fees			\$	
	Printing and Engraving Costs			\$	
	Legal Fees		×	\$	140,000.00
	Accounting Fees			\$	
	Engineering Fees			\$	
	Sales Commissions (specify finders' fees separately)			\$	
	Other Expenses (identify) Blue Sky		×	\$	800.00
	Total		<u> </u>	\$	140 800 00

......

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENS	ES A	ND USE OF PRO	OCEI	EDS	
	b. Enter the difference between the aggregate offering price given in respon Part C - Question 1 and total expenses furnished in response to Part C - Que 4.a. This difference is the "adjusted gross proceeds to the issuer."	stion			\$	34,859,200.63
5.	Indicate below the amount of the adjusted gross proceeds to the issuer use proposed to be used for each of the purposes shown. If the amount for any pur is not known, furnish an estimate and check the box to the left of the estimate. total of the payments listed must equal the adjusted gross proceeds to the issue forth in response to Part C – Question 4.b above.	rpose The				
	:		Payments to Officers, Directors & Affiliates			Payments to Others
	Salaries and fees.	\$_	<u> </u>		\$	
	Purchase of real estate	\$_			\$	
	Purchase, rental or leasing and installment of machinery and equipment	\$		×	\$	2,000,000.00
	Construction or leasing of plant buildings and facilities	\$		×	\$	9,000,000.00
	Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)	\$			\$	
		\$			\$	
		• – \$		×	\$	23,859,200.63
		· - \$			\$	
		_			•	
		\$_			\$	
	Column Totals	\$_	0	×	\$	34,859,200.63
	Total Payments Listed (column totals added)		ዾ \$	34,83	59,20	0.63
	D. FEDERAL SIGNATURE	£				· · · · · · · · · · · · · · · · · · ·
the wr	te issuer has duly caused this notice to be signed by the undersigned duly authorize following signature constitutes an undertaking by the issuer to furnish to the latten request of its staff, the information furnished by the issuer to any non-accele 502.	U.S.	Securities and Ex	chang	e Co	mmission, upon
Iss	uer (Print or Type) Signature		Date		-	
	Raven biotechnologies, inc.	the	Dec	embe	r (0 ,	2002
Na	me of Signer (Print or Type) Title of Signer (Print or Type)					
	Jennie P. Mather, Ph.D. President and Chief Executiv	ve Of	ficer			

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)